Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in refractory primary immune thrombocytopenia
ChiCTR2100051890Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Kunming Medical University
- Start
- Nov 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of telitacicept in immune thrombocytopenia (ITP) (3 arms), sponsored by Second Affiliated Hospital of Kunming Medical University. Primary endpoint: Platelet count. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2100051890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051890.